Gene Therapy Clinical TrialsGene Therapy Clinical Trials

Cancer Gene TherapyThree Basic Approaches.

Genetically alter a person's immune cells that are already naturally targeted to kill cancer cells.

Take cancer cells from the body and alter them genetically so that they elicit a strong immune response. These cells can then be returned to the body to act as a type of cancer vaccine. Inject a tumor with a gene that renders the tumor cells vulnerable to an antibiotic or other drug.

Cancer Gene TherapyThree Basic Approaches.

Genetically alter a person's immune cells that are already naturally targeted to kill cancer cells.

Take cancer cells from the body and alter them genetically so that they elicit a strong immune response. These cells can then be returned to the body to act as a type of cancer vaccine. Inject a tumor with a gene that renders the tumor cells vulnerable to an antibiotic or other drug.

Ablation of c-Myb function might be an effective approach for the therapy of chronic myelogenous leukemia or other c-myb-dependent malignancies.

Ablation of c-Myb function might be an effective approach for the therapy of chronic myelogenous leukemia or other c-myb-dependent malignancies.

Antibodies against Oncogene Protein Products

“A Phase-I trial showed that a recombinant human monoclonal antibody against vascular endothelial growth factor (called anti-VEGF-MAbanti-VEGF-MAb) was well-tolerated among a group of 25 patients with metastatic cancers. After four treatments in 72 days, 13 patients had stable disease and one patient with renal cell carcinoma had a 39 percent reduction in tumor size.”

“A Phase-I trial showed that a recombinant human monoclonal antibody against vascular endothelial growth factor (called anti-VEGF-MAbanti-VEGF-MAb) was well-tolerated among a group of 25 patients with metastatic cancers. After four treatments in 72 days, 13 patients had stable disease and one patient with renal cell carcinoma had a 39 percent reduction in tumor size.”

In one ovarian cancer trial, a genetically engineered respiratory virus that carries a p53 gene will be periodically infused into the abdominal and pelvic cavity. The p53 gene is a tumor suppressor that is mutated in many different types of cancer, including 57% of ovarian cancers.

In one ovarian cancer trial, a genetically engineered respiratory virus that carries a p53 gene will be periodically infused into the abdominal and pelvic cavity. The p53 gene is a tumor suppressor that is mutated in many different types of cancer, including 57% of ovarian cancers.

Gene therapy for

Familial Hyper-cholesterolemi

a

http://www.sigmaxi.org/amsci/articles/99articles/Kmieccap12.html